Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Summary

The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.

Timeline

Start

2021-06-10

Primary completion

2023-12-26

Completion

2023-12-26

Outcome

Met primary endpoint

release “SPH3127片III期临床试验确证性研究（SPH3127-301第二阶段）主要研究终点结果达到方案预设的终点指标。” sphchina.com ↗

Publications

• Lv Q, Ma C, Wang F, Li L, Xiong G, Li Z, Qu Y, Pang W, Xiao W, Ruan H, Wei L, Liu G, Zhang J, Liu Q, Lin L, Long M, Li H, Yuan H, Liu L, Gao Y, Liu P, Zhang C, Wang Z, Xie J, Wang J, Zhang X, Lu Y, Huang K, Liu M, Chen J, Gao X, Wang D, Ma X, Chen X, Li Y, Zhang Y, Kong X, Chen F, Zhang X, Qi J, Cao Y, Huang Y, Zhang Y, Cui W. Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial. Drugs. 2026 Jul;86(7):1121-1132. doi: 10.1007/s40265-026-02315-z. Epub 2026 May 21.

Drugs

Indications